R-Tech Ueno: Announcement of Commercial Availability of RESCULA® Eye Drops in the U.S. Market

  R-Tech Ueno: Announcement of Commercial Availability of RESCULA® Eye Drops
  in the U.S. Market

Business Wire

TOKYO -- February 21, 2013

R-Tech Ueno (JASDAQ:4573):

Sucampo Pharmaceuticals, Inc. (hereinafter referred to as "Sucampo") announced
that RESCULA^® Eye Drops had been launched in the U.S. market. (See Sucampo's
press release dated February 19, 2013.)

RESCULA^® Eye Drops may be used as a first-line agent or concomitantly with
other topical ophthalmic drug products with ocular hypotensive effect for
treatment of open-angle glaucoma, which is the most common form of glaucoma,
or ocular hypertension. RESCULA^® Eye Drops is a BK channel activator, which
is different from other intraocular pressure-lowering agents.

Contract for assignment of marketing approval and dealership of RESCULA^® Eye
Drops, licensing of related patents, and exclusive manufacturing and provision
of the product in the U.S. and Canada for indications of glaucoma and ocular
hypertension was made between Sucampo and us in April 2009.

The above venture will not contribute to any revision of the full-year
earnings estimates pre-announced on February 12, 2013.

  *About RESCULA^® ophthalmic solution :

RESCULA^® is a glaucoma/ocular hypertension treatment drug that was the first
in the world to utilize Prostone. RESCULA^® has a pharmacological effect as an
ion channel opener. There are reports that RESCULA^® has not only an ocular
pressure decreasing action but also an optic nerve protective action (in
vitro) and an action to improve ocular blood flow in normal tension glaucoma.
It has been approved in 45 countries all over the world since it was marketed
in Japan in 1994.
RESCULA^® was originally approved by the FDA in 2000. Sucampo had been making
a supplemental New Drug Application about RESCULA^®.

  *About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the
purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a
medical doctor, the company is developing new drugs on the theme
"Physician-Oriented New Drug Innovation", targeting ophthalmologic and
dermatologic diseases that previously had no effective therapeutic agent.
We aim at becoming a "global pharmaceutical company specializing in specific
fields (ophthalmology and dermatology) and developing and selling
pharmaceutical products through the eyes of doctors." We are promoting the
development of new drugs for unmet medical needs for which the government
provides recommendations and assistance, orphan drugs and the drugs in the
field of anti-aging (lifestyle drugs).

  *About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones,
which occur naturally in the human body as a result of enzymatic, 15-PGDH,
transformation of certain fatty acids, was first identified by Ryuji Ueno,
M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman, Chief Executive Officer
and Chief Scientific Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996
with co-founder.
For more information about Sucampo Pharmaceuticals, please visit
www.sucampo.com.

Contact:

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business Management Department
info@rtueno.co.jp
 
Press spacebar to pause and continue. Press esc to stop.